Hazlett, Burt & Watson’s Edwards Lifesciences EW Stock Holding History

Hazlett, Burt & Watson’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-141	Closed	-$10K	–	810
2025 Q1	$10K	Hold	141	–	–	﹤0.01%	564
2024 Q4	$10K	Hold	141	–	–	﹤0.01%	538
2024 Q3	$9K	Hold	141	–	–	﹤0.01%	543
2024 Q2	$13K	Hold	141	–	–	0.01%	497
2024 Q1	$13K	Sell	141 -564	-80%	-$47.4K	0.01%	485
2023 Q4	$54K	Hold	705	–	–	0.04%	294
2023 Q3	$49K	Hold	705	–	–	0.04%	302
2023 Q2	$66K	Sell	705 -540	-43%	-$46.9K	0.05%	265
2023 Q1	$103K	Hold	1,245	–	–	0.08%	187
2022 Q4	$93K	Sell	1,245 -36	-3%	-$2.77K	0.08%	191
2022 Q3	$106K	Sell	1,281 -213	-14%	-$20.5K	0.1%	173
2022 Q2	$141K	Hold	1,494	–	–	0.13%	159
2022 Q1	$176K	Buy	+1,494	New	+$168K	0.14%	152

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Hazlett, Burt & Watson's EW Position: Q2 2025 in Review

Hazlett, Burt & Watson sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 141 shares — an estimated $10K sold.

Hazlett, Burt & Watson first reported a position in EW in Q1 2022 and held it in 13 quarters. The position peaked at $176K in Q1 2022. 1,260 funds tracked by Wall St. Rank hold EW as of Q2 2025.

Hazlett, Burt & Watson reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
Hazlett, Burt & Watson sold 141 Edwards Lifesciences shares in Q2 2025, an estimated $10K.
Hazlett, Burt & Watson first reported a position in Edwards Lifesciences in Q1 2022 and held it in 13 quarters.
Hazlett, Burt & Watson's Edwards Lifesciences position peaked at $176K in Q1 2022.
1,260 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2025, filed 25 Jul 2025.